Back to company

ELDON BIOLOGICALS A/S: Financial statements 2022

CVR: 26747007

ELDON BIOLOGICALS A/S (CVR 26747007) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 16,382,652 and a net result of DKK 4,971,816 compared with DKK 9,098,419 the year before. That is a decrease of 16.1% compared with the year before. Equity amounted to DKK 29,619,290. The solvency ratio was 83.5%. The company had 9 employees in the financial year.

Gross Profit
16,382,652 kr.
Profit/Loss
4,971,816 kr.
Equity
29,619,290 kr.
Total Assets
35,481,576 kr.
Employees
9

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022-16.4 mio.5 mio.29.6 mio.9
2021-19.5 mio.9.1 mio.25.1 mio.11
2020-14.3 mio.6.6 mio.16.5 mio.8
2019-9.5 mio.3.3 mio.10.5 mio.6
2018-9.5 mio.3.8 mio.7.1 mio.7

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on ELDON BIOLOGICALS A/S

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

About ELDON BIOLOGICALS A/S

ELDON BIOLOGICALS A/S is a Danish company of the type Aktieselskab based in Gentofte, founded in 2002. The company is registered under the industry Fremstilling af andre kemiske produkter i.a.n.. The management consists of Kasper Juul Hedegaard. The company is owned by MEDI-TRADE ApS and HOLDINGSELSKABET MLH ApS. The company has 9 employees. In 2025, the company reported a gross profit of DKK 13,635,058 and a net result of DKK 3,900,353 compared with DKK 6,673,643 the year before. Equity amounted to DKK 42,055,949.